Announcements Trials

Browse Landscape

Status

Not yet recruiting 1

Sponsor Class

Study Type

Observational 1

Sponsor

Cancer Type

Other solid neoplasm 1

Conditions

Gastrointestinal Stromal Tumors 2 Colorectal Neoplasms 2 Biliary Tract Neoplasms 2 Advanced or Metastatic Solid Tumors 2 Thymoma 1 Solid Tumor 1 Sarcoma 1 Piebaldism 1 Osteosarcoma 1 Nasopharyngeal Carcinoma 1 Endometrial Neoplasms 1 Cholangiocarcinoma 1 Carcinoma, Renal Cell 1 Carcinoma, Non-Small-Cell Lung 1 Carcinoma, Hepatocellular 1 Advanced Solid Tumor 1 Advanced Renal Cell Carcinoma (aRCC) 1 Advanced Refractory Solid Tumors 1

Interventions

Injections 13 pembrolizumab 10 tislelizumab 9 toripalimab 6 atezolizumab 4 Nivolumab 4 Carboplatin 3 trastuzumab deruxtecan 2 olaparib 2 lenvatinib 2 Pemetrexed 2 Paclitaxel 2 Oxaliplatin 2 Gemcitabine 2 Fluorouracil 2 Docetaxel 2 Cyclophosphamide 2 Cisplatin 2 Cetuximab 2 Bevacizumab 2 zimberelimab 1 talazoparib 1 spartalizumab 1 sotorasib 1 serabelisib 1 penpulimab 1 niraparib 1 nedaplatin 1 mirdametinib 1 fludarabine phosphate 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Advanced Solid Tumor × envafolimab × 1 year × Clear all

NCT07562347 2026-05-01

ENCOMPASS STUD

IR INNOVATE RESEARCH PRIVATE LIMITED

Not yet recruiting

Other solid neoplasm

Advanced Solid Tumor

Data powered by HemOnc (CC BY 4.0) Colophon ⚡